Introduction
A positive correlation between dose-intensity of antineoplastic drugs and response rate has been reported for several human tumours [1, 2] . As dose and frequency of administration of many e¡ective anti-neoplastic agents are limited by myelosuppression, recombinantly derived haematopoietic growth factors (or colony-stimulating factors (CSF)) that stimulate proliferation and di¡erentiation of haematopoietic progenitor cells into mature e¡ector cells [3^5] were expected to allow for dose-intensi¢cation without haematopoietic stem-cell support [6, 7] . Early clinical studies of the e¡ects of the haematopoietic growth factors GM-CSF and G-CSF suggested bene¢cial e¡ects on neutrophil recovery [81 1] which would allow the administration of larger than usual doses of cytotoxic drugs [12] . However, to date there has been no well-controlled study that has convincingly demonstrated if and to what extent CSF makes dose escalations of myelosuppressive drugs possible. We now report on the ¢rst randomized placebo-controlled doubleblind dose escalation study to determine and quantify the magnitude of increase in dose escalation that can be attributed to GM-CSF support.
Patients and methods

Patients
The design of the Dexa-BEAM þ GM-CSF protocol was in accordance with the declaration of Helsinki. It had been approved by the local institutional review board at the study center, the University of Cologne. Written informed consent was obtained from all patients prior to randomization. Sixty consecutive patients, 18^60 years of age (median 31 years) from 25 centers with histologically proven Hodgkin's disease, who had failed to respond to or had relapsed after a remission achieved by multi-drug chemotherapy, were randomized to receive Dexa-BEAM salvage therapy [13] with either placebo or E. coli-derived human recombinant GM-CSF (Schering-Plough). Inclusion criteria were: primary treatment with cyclophosphamide, vincristine, procarbazine, and prednisone plus doxorubicin, bleomycin, vinblastine, and dacarbazine (COPP + ABVD), or plus ifosfamide, methotrexate, etoposide, and prednisone (COPP + ABV + IMEP) chemotherapy [14, 15] , or comparable regimens with and without radiotherapy; progressive disease or relapse for which salvage radiotherapy was not considered to be a curative option; and curative intent. The characteristics of the patients and their response to prior chemotherapy are listed in Table 1 .
Treatment
The Dexa-BEAM regimen was given as described [13] 2 subcutaneously starting day 8 until neutrophil counts had recovered to 41000/mm 3 for two consecutive days. Treatment was repeated on day 29. Patients with chemotherapy-sensitive disease (as indicated by the achievement of a complete or partial remission after two cycles of Dexa-BEAM) were o¡ered subsequent high-dose chemotherapy (HDCT) followed by autologous bone marrow or peripheral blood stem-cell transplantation (ABMT). The myeloablative regimen consisted of the CVB regimen [16] . Responding patients who did not undergo HDCT/ABMT received four cycles of Dexa-BEAM.
Dose escalation
The maximal tolerated dose (MTD) was estimated for the ¢rst Dexa-BEAM cycle only, because further treatment was not uniform (drop outs due to progressions, continuation with HDCT/ABMT). MTD was de¢ned as the dose level at which patients have a 1/3 probability to experience a dose-limiting event. The following events were de¢ned as dose-limiting: (1) recovery of neutrophils (41000/mm 3 ) later than day 24; (2) recovery of platelet count (4100,000/mm 3 ) later than day 32; (3) extramedullary toxicicity of WHO grade 4 (with the exception of emesis and alopecia), including therapy-related deaths.
A generalization to parallel accrual of the up and down sampling scheme described by Storer [17] was developed to determine the etoposide dose level for a new patient. Sampling was done independently for the two randomization arms. The sampling algorithm made use of all the information on toxicities and dose-limiting events observed in the ¢rst Dexa-BEAM cycle of patients who had been treated in the respective treatment arm before. Essentially, a patient was assigned to the next higher dose level once two patients in the respective treatment arm, who had been treated at the current or a higher dose level, did not experience a dose-limiting event. The dose level for a new patient was decreased by one step if a patient in the same treatment arm experienced a dose-limiting event at the current or a lower dose level. Toxicity results that did not have an immediate e¡ect on the current dose by these rules were queued to have an e¡ect in case a change in the current dose level rendered them relevant. Using this sampling scheme the current dose level oscillates stochastically around the mximal tolerated dose.
Toxicities were analysed conditionally on the sampling using a logistic regression including dose level and GM-CSF as covariates [17] . White blood counts during the ¢rst cycle were determined daily or at least every other day and were analyzed using patient-wise cubic spline interpolation (under visual control) to extract four parameters to characterize the course of the white blood cell counts: (1) ¢rst day 52500/mm 3 ; (2) day of nadir; (3) level of nadir; and (4) ¢rst day 42500/mm 3 . Separate linear regression was used to determine the e¡ect of dose level and GM-CSF on these characteristics.
Relative dose intensities of the maximal tolerated dose levels achieved in each treatment arm were calculated using previously described methods [18] .
Evaluation of therapy
The extent of disease was assessed by chest X-ray, abdominal sonogram and/or computerized tomography, bone marrow and liver biopsy. After therapy all disease manifestations were reassessed by adequate methods. All patients who started therapy were considered evaluable for toxicity and response. Complete response (CR) was de¢ned as the disappearance of all measurable disease for at least four weeks after the end of treatment, and partial reponse (PR) was de¢ned as a 450% reduction of the measurable tumour mass for at least four weeks and disappearance of systemic symptoms. Death within six weeks from the initiation of Dexa-BEAM therapy from causes other than refractory disease was designated as therapy-related death. Survival (SV) and freedom from treatment failure (FFTF) of all patients were determined as the time from the beginning of salvage therapy to death or failure, respectively.
Results
Of the 60 patients included in this trial, thirty were randomized to receive GM-CSF and thirty to receive placebo, respectively, starting day 8 of each Dexa-BEAM cycle. The patients were well balanced for known risk factors such as stage and symptoms, organ involvement at diagnosis and at relapse, number of and response to previous therapies (Table 1) .
Maximal tolerated etoposide dose levels and relative dose intensities
The toxicities and dose limiting events of the ¢rst Dexa-BEAM cycle were investigated by the study center by a phone call to the participating institution three and four weeks after the start of therapy. By adapting the dose based on this information from treated patients, the sampling dose level stochastically approached the maximal tolerated dose in both treatment arms ( Figure 1 ). No dose-limiting event occurred in either treatment arm up to dose level 3. The predominant dose-limiting events were neutropenia and associated infections. Seven dose-limiting events occurred in the 30 patients with placebo: three at level 4 (prolonged neutropenia, prolonged thrombocytopenia, and a fatal infection during neutropenia), one at dose level 5 (prolonged neutropenia), two at level 6 (a fatal pneumonia and a grade 4 infection during neutropenia) and one at level 8 (grade 4 neurological disturbance during neutropenic sepsis). In the group of patients who received GM-CSF, four experienced toxic events at dose levels 5, 7 (two events), and 8. These events consisted of prolonged neutropenia at dose level 5, prolonged neutropenia combined with thrombocytopenia and combined neutro-thrombocytopenia with grade 4 stomatitis at dose level 7, and a fatal staphylococcus sepsis with ARDS at dose level 8. The probability of experiencing a dose-limiting event at a given dose level was ¢tted into a logistic regression analysis. Dose level had a signi¢cant (P 5 0.02) e¡ect on the probability of a toxic event (Figure 2 ). The maximal tolerated dose, which was de¢ned as the probability of 33% per cycle to experience a dose-limiting event was reached by patients receiving placebo at the dose level 5.8 (80% con¢dence interval (CI): 4.4^7.2), corresponding to 1160 mg/m 2 etoposide per cycle, while the eoposide dose could be increased with GM-CSF support by 65% to 1920 mg/m 2 or dose level 7.8 (80% CI: 6.4^8.7), respectively. This di¡erence was signi¢cant in a onesided test with P = 0.045 (P = 0.09, two-sided). Thus, a considerable escalation of the etoposide dose was possible with and without GM-CSF, with GM-CSF support allowing for an additional, yet moderate dose escalation when compared to placebo. Using previously described methods for the calculation of relative dose intensities [18] , the di¡erence in the dose escalation possible with and without CSF corresponds to an additional increase in dose intensity of 13% with GM-CSF, if the calculation is based on ¢ve drugs (including dexamethasone) and 16%, respectively, if only the four cytotoxic drugs included in the four-week Dexa-BEAM regimen are considered.
Severe myelosuppression with temporary neutropenia 5500/mm 3 and thrombocytopenia 550,000/mm 3 was observed at all dose levels. Leukocytopenia occurred earlier (P = 0.0004), had a lower nadir and lasted longer with increasing dose levels. The ¢rst day 42500/mm 3 was dose-independent, but recovery was reached 1.5 days earlier with GM-CSF when compared to placebo (P = 0.04, two sided; Figure 3 ).
Patients without a dose-limiting event after the ¢rst cycle were to continue at the same dose level to which they had been assigned to for the ¢rst cycle. Twentyeight patients (fourteen in each arm) who responded after two Dexa-BEAM cycles proceeded to high-dose myeloablative therapy followed by ABMT or PBSCT. There was no signi¢cant di¡erence in the rate of toxic events in subsequent cycles between patients with GM-CSF or placebo, suggesting that the use of GM-CSF did not result in haematopoietic stem-cell damage or depletion.
Other toxicities
The non-haematological toxicities included mucositis (grades 1 and 2), nausea and vomiting (grade 1) and alopecia (grades 2 and 3) and occurred with the same frequency and severity in the two treatment arms. Anemia Figure 1 . Evolution of the dose escalation of etoposide in the Dexa-BEAM regimen with GM-CSF and placebo during the recruitment phase of the trial. The dose level for a new patient was increased by one step for every two patients in the respective treatment arm treated at the current dose level or above who did not experience a dose-limiting event, while the dose level for a new patient was decreased by one step if a dose-limiting event occurred at the current dose level or below. While four dose-limiting events at levels 5, 7 (two patients), and 8, respectively, occurred in patients who received GM-CSF, seven doselimiting events were observed at levels 4 (three patients), 5, 6 (two patients) and 8, respectively, in patients who received placebo. Figure 2 . Probability of dose-limiting events. As shown from the logistic regression curves, dose level had a signi¢cant (P 5 0.02) e¡ect on the probability of a toxic event. The curve for patients treated with placebo crossed the 33% probability per cycle for a dose-limiting event at dose level 5.8, while this probability was reached with GM-CSF at a dose level 7.8, demonstrating that GM-CSF allows for an additional dose escalation (P = 0.045, one-sided).
and thrombocytopenia requiring transfusion of packed red cells and platelets, respectively, were not di¡erent in the placebo and CSF group; in particular, time to platelet recovery was not prolonged in the patients who recieved GM-CSF when both groups were analyzed according to a given dose level. Injection reaction sites, low-grade fever and £ushing were more common in patients receiving GM-CSF, but this did not lead to dose reductions or even refusal of further therapy by the patient.
Response to therapy
There were thirty-one complete remissions (52%) and three partial remissions, with an overall response rate of 57% (95% con¢dence limits: 43%^69%). No radiotherapy to bulky and/or residual nodal disease was given. Eight patients (13%) died of treatment-related complications (pneumonia, pulmonary embolism, postsurgical death after laparotomy because of suspected ileus, carmustineinduced pneumonia after ABMT, and four septicemias). The response rates were not di¡erent between the two treatment arms (Table 2) . Similarly, responses to therapy were not di¡erent in the 31 patients who were treated at dose level 1^4 when compared to the 29 patients who were treated at dose levels 5^8. Overall survival was a¡ected by the time of failure to primary therapy (one year within diagnosis vs. later; Figure 4a ), but not by the addition of GM-CSF (Figure 4b ).
Discussion
While there have been randomized trials that evaluated the e¡ect of CSF on dose intensity by shortening treatment intervals with ¢xed doses of cytotoxic drugs [19, 20] , there have been no reports on randomized studies that have determined and quanti¢ed the magnitude of dose escalation that can be achieved with haematopoietic growth factor support in comparison to placebo. Several prerequisites must be ful¢lled for such a study: a regimen with myelosuppression as the dose-limiting side e¡ect and a strict correlation between the dose level and the probability of a dose-limiting event. This was the case in this trial, since the maximal tolerated dose of the Dexa-BEAM regimen was de¢ned by prolonged neutropenia and associated events and not by other side e¡ects that cannot be expected to be ameliorated by the haematopietic growth factor given.
Our Dexa-BEAM dose escalation study shows that by applying liberal, yet prede¢ned criteria for dose-limit- Progressive disease (%) 12 (39) 4 (14) 16
Therapy-related deaths 8 Figure 3 . E¡ect of GM-CSF on neutrophil counts after Dexa-BEAM with etoposide dose levels 2 and 6. The descending arm was not a¡ected by GM-CSF, while the neutrophil recovery was accelerated using GM-CSF by 1.5 days. This e¡ect was observed at all dose levels. ing events, which anticipated and allowed prolonged neutropenia, etoposide can be escalated considerably even without GM-CSF support. Etoposide was chosen as the drug to be escalated because etoposide can be given up to a dose of 3.5 g/m 2 without stem cell support [21] . The complete response rate of 52% is encouraging. However, maximally escalated Dexa-BEAM proved to be quite toxic with fatality rates comparable to induction chemotherapy regimens which are given for the treatment of acute leukemias. The toxicity was judged to be acceptable in the light of the dim prognosis of patients with Hodgkin's disease relapsing after primary chemotherapy [22] . As no therapy-related deaths were observed up to dose level 3, this dose level, rather than the maximal tolerated dose levels 5.8 and 7.8 without and with GM-CSF, respectively, would be suggested outside clinical trials.
Compared to placebo, the etoposide dose could be escalated considerably further with GM-CSF, from 1160 mg/m 2 to 1920 mg/m 2 or 65%. However, this reached signi¢cance only in a one-sided test (P = 0.045) and only if exlusively etoposide dose levels were considered. With regard to the overall dose and relative dose-intensity, the gain provided by GM-CSF was small: 13% more dose intensity based on a calculation that includes all ¢ve drugs of the Dexa-BEAM regimen and 16% increase, if only the four cytotoxic drugs are taken into consideration. Even if one considers the earlier leukocyte recovery observed after GM-CSF which would allow recycling of the regimen on day 19.5 instead of 21, this would translate into gains of relative dose intensities of only 14% and 18%, respectively.
While the aim of this study was the quanti¢cation of the role of haematopoietic growth factors in permitting dose escalations and explicitly not the evaluation of the role of dose intensi¢cation in the treatment of lymphomas, it is not suprising that the small additional gain in dose intensity that was achieved by GM-CSF in comparison to placebo did not translate into higher remission rates, time to treatment failure (data not shown) or overall survival rates.
In contrast to other studies, where CSF-supported dose escalation failed due to reasons other than neutropenia [23^26], the failure of GM-CSF in our study was due to insu¤cient abrogation of neutropenia, the primary task of this CSF. It might be argued that choosing patients with relapsing or refractory Hodgkin's disease who have gone through prior chemotherapy could have been a bias against the e¤cacy of GM-CSF, as the bone marrow reserves of these patients might have been compromised prior to the administration of GM-CSF. That this is not the case is demonstrated by the fact that in all 28 attempted cases (14 in each arm) peripheral blood stem cell or bone marrow harvests yielded excellent results after Dexa-BEAM.
The E. coli-derived GM-CSF as used in this study was well tolerated and the application scheme was strictly adhered to. Injection reaction sites, low-grade fever and £ushing were the only GM-CSF related side e¡ects.
They did not cause any dose reductions or even refusal of further therapy by the patient. It is therefore unlikely that results of this study would have been di¡erent, had yeast-derived GM-CSF been used instead of the E. coliderived GM-CSF, the former having the advantage of being less toxic than the bacteria-derived product [27] .
Even though granulocyte-colony-stimulating factor (G-CSF) has been reported to be more e¡ective than GM-CSF in accelerating haematopoietic recovery after chemotherapy [28, 29] , studies on the value of G-CSF in escalating dose or increasing dose-intensity are as controversial as those for GM-CSF [10, 25, 30, 31] . Thus it seems that neither CSF permits a clinically relevant dose escalation of cytotoxic drugs. Considering the suprisingly high-dose escalation possible with placebo alone, one must suspect that many of these studies did not take into consideration that modern supportive therapy other than haematopoietic growth factors allows for a considerable dose escalation that would not have been anticipated previously [12, 32] .
Previous randomized and non-randomized studies had come up both with positive [33^37] and negative results [38^41] regarding the e¤cacy of CSF in dose intensi¢ca-tion. Several trials indicate that CSF can contribute to increased dose intensities by permitting shorter intervals between treatment cycles rather than by allowing escalated doses. All positive randomized studies that show a bene¢cial e¡ect of CSF [19, 20, 42^47] used the haematopoietic growth factors primarily for interval reduction rather than for dose escalation. The time-saving e¡ect of CSF depends on the aggressiveness of the respective chemotherapy regimen and is most pronounced after chemotherapy regimens with low neutropenic risk, where neutrophil recovery can be accelerated by up to 4.5 days [48] compared to placebo, while the di¡erence to placebo after chemotherapy with high neutropenic risk (e.g., the Dexa-BEAM regimen used in this study) or even myeloablative therapy is usually in the range of only one to two days.
With the failure of CSF to permit signi¢cant increases in dose escalation without stem cell support in wellcontrolled, i.e., randomized studies, much of the enthusiasm that accompanied the advent of the recombinant human haematopoietic growth factors several years ago is fading. While CSF is very e¡ective in mobilizing peripheral blood stem cells for stem-cell harvest before high-dose chemotherapy with stem-cell support [49] and has been shown to reduce the likelihood of febrile neutropenia, when the expected incidence is 440% [50] , our study shows that it permits only small-range dose escalations. When increased dose intensity is the goal, reducing treatment intervals rather than dose escalations is the more e¡ective strategy for the use of CSF.
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